lacking, 1 2 and alternative techniques have been suggested and introduced into clinical practice in recent years. For instance, measurement of CO by transpulmonary thermodilution has been proposed. 3 4 In this technique, a thermistor-tipped catheter is typically placed in the arterial system for the detection of the thermodilution time curve. Previously, a number of experimental and clinical studies showed that the measurement of CO by the transpulmonary thermodilution technique is comparable with that by a pulmonary artery catheter or other techniques. 5 -9 Very recently, a new system based on pulse contour analysis without in vivo calibration (Vigileo w ) has been developed and introduced into clinical practice. In this system, using the shape of the arterial pressure curve form, an arterial pressure CO algorithm is incorporated, which relates the blood flow to the arterial pressure using a haemodynamic model. The model uses basic cardiovascular haemodynamic concepts according to which the arterial circulation, acting as an elastic storage system, transforms the discontinuous flow owing to the pumping of the heart into steady flow in the peripheral organs.
The algorithm, which requires demographic patient data, is suggested to be robust to represent the flow-pressure relationship. So far, the data suggest that CO can be derived reliably by this technique when compared with pulmonary artery catheter (PAC)-based measurements. 10 However, these results as obtained in small patient populations are not convincing, and more recent studies 11 12 questioned the reliability of this system. In this study, we evaluated the Vigileo w system against transpulmonary thermodilution, which itself can be regarded as being as reliable as pulmonary arterial thermodilution in patients with septic shock under actual clinical conditions, i.e. changes in mean arterial pressure (MAP).
Methods
After approval by our local ethics committee, we enrolled 24 mechanically ventilated patients with septic shock (16 male, 8 female, age 26-77 yr) requiring treatment with norepinephrine, who for clinical indication underwent extended haemodynamic monitoring by the transpulmonary thermodilution technique (PiCCOplus w , Pulsion Medical Systems, Munich, Germany). All patients suffered from abdominal sepsis and were managed according to international guidelines on the treatment of patients with sepsis. 13 Each patient had a 5F femoral arterial thermistor catheter (PV20L15, Pulsion Medical Systems, Munich, Germany) in situ. This system allows the determination of CO, intrathoracic blood volume (ITBV), extravascular lung water (EVLW) and global ejection fraction (GEF). 14 -16 In general, pressure transducers were calibrated against atmosphere at the mid-chest level. In parallel to haemodynamic monitoring by the transpulmonary thermodilution technique, we applied continuous CO measurements by arterial pulse contour analysis from the femoral arterial pressure curve (FloTrac w pressure sensor, Vigileo w monitor, Edwards Lifesciences, Irvine, CA, USA) with the software version V01.07, PIC V1.0. On the basis of the analysis of the shape of the arterial pressure form, an algorithm which relates the blood flow to the arterial pressure using a haemodynamic model enables determination of CO. The model uses basic cardiovascular haemodynamic concepts according to which the arterial circulation, acting as an elastic storage system, transforms the discontinuous flow owing to the pumping of the heart into steady flow in the peripheral organs. The algorithm requires demographic patient data, i.e. gender, age, height, weight and body surface area. This system enables the measurement of CO and also calculates the peripheral vascular resistance. The software for this device calculates CO every 20 s on the basis of the last 20 s interval of arterial waveform analysis. Before the measurements, the pulse contour system was allowed to stabilize over a 10 min interval. No damping of the arterial pressure line, which could be achieved in all patients, was also a prerequisite for the measurements. After a baseline measurement of CO (baseline), MAP was elevated by increasing norepinephrine dosage (intervention), and control measurements were obtained after returning to baseline MAP values by reducing norepinephrine dosage (control). A MAP of approximately 90 mm Hg was targeted. At each time point, measurements were obtained about 5 min after reaching stable MAP, and the duration of the whole study period was about 15 min. Fluid status and ventilator settings remained unchanged throughout the study period. For clinical reasons, all patients were sedated and ventilated in a pressure-controlled mode (BiPAP, Evita 4, Draeger, Luebeck, Germany). In particular, airway pressures and the inspiratory oxygen fraction (FI O 2 ) remained constant in all patients. At each time point, CO by transpulmonary thermodilution was obtained from three central venous bolus injections of 15 ml of ,88C cold normal saline. Before each injection, pulse contour CO was read from the Vigileo w monitor. Vigileo w CO values were obtained as the mean of the three values. Injections were made manually and not triggered by the respiratory cycle. The variation of the CO measurement was assessed by the coefficient of variation (CV), which was calculated within each patient and for each time point, and is calculated as CV¼SD/mean (%).
Statistical analysis
All data are given as mean (SD). Haemodynamic parameters at the three time points were compared by an analysis of variance (ANOVA) on ranks and an all-pair-wise comparison procedure (Student -Newman -Keuls method). For the comparison of CO measurements and agreement between the two techniques, linear regression analysis and the Bland -Altman method (mean bias, SD) were applied. Limits of agreement were defined by 2 SD. Furthermore, this type of analysis was performed separately for each time point, and a comparison between regression coefficients for all time points was made. Finally, changes in both techniques were correlated against each other by linear regression analysis. Statistical significance was considered at P,0.05. For the statistical analysis, we used SigmaStat w for Windows (version 1.0).
Results
Mean age was 58 (12) Table 1 . Heart rate, central venous pressure, GEF and EVLW were not different between the three time points. MAP was significantly higher during increased norepinephrine dosages as was systemic vascular resistance. It is noteworthy that, while CO(TPID) was unchanged, CO(Vigileo w ) was not only different between baseline and intervention but also between baseline and control (Table 2) .
Overall, the range of CO was 3. (Fig. 6) . As one patient (no. 10) was an extreme outlier, we re-analysed our data without this particular patient. However, the results were similar, as we found an overall correlation of r 2 ¼0.13 (n¼69).
As a measure of measurement variability, we calculated the CV for each time point and for each patient. Mean CVs were 5.8, 6.7 and 5.2% for CO(Vigileo w ) and 6.7, 6.7 and 6.7% for CO(TPID) at the three time points.
Discussion
Our data show that the measurement of CO by pulse contour analysis using a system without in vivo calibration (Vigileo w ) underestimates CO(TPID) and does not correlate well with transpulmonary thermodilution. Furthermore, changes in both techniques were also only poorly In this study, we used the transpulmonary thermodilution technique as the reference technique, which has been extensively compared with the clinical 'gold standard', i.e. pulmonary artery thermodilution. Previous experimental 5 -7 and clinical studies 4 8 reported a good correlation between pulmonary artery and transpulmonary thermodilution for the measurement of CO. However, transpulmonary thermodilution CO is most often found to be higher than the corresponding pulmonary artery CO, and this is considered to be caused by the cold-induced reduction in the heart rate 17 and the loss of indicator. 18 Furthermore, Bock and colleagues 7 showed that the early recirculation of the cold is responsible for the broader thermodilution curve in the aorta, thus leading to about 3 (4)% higher values for CO.
Most recently, a less invasive device for continuous CO measurement (CCO), based on peripheral arterial pulse contour analysis (Vigileo w ), has been introduced into clinical practice. This system does not require thermal or dye dilution, but rather bases its calculations on arterial waveform characteristics in conjunction with patient demographic data without requiring calibration against another method. The system has been assessed and found to be robust and accurate over a wide range of CO and clinical conditions. 19 However, only few clinical data have been available so far on the accuracy of this system, especially in critically ill patients. Manecke and colleagues 10 used data from 11 cardio-thoracic surgical patients with an unequal number of measurements per patient taken immediately after surgery and compared 65 pairs of CO measurements. The mean bias between pulse contour CO and intermittent pulmonary artery CO (ICO) was 0.04 (0.99) litre min 21 . However, because an unequal number of measurements per patient was used, which is a statistically inappropriate procedure, these results may be questionable. McGee and colleagues 20 analysed 252 data points in 36 patients [mean age 64 (14) yr, 72.2% male] and reported that pulse contour CO trends correlated with ICO in 98% of all data points collected.
In patients after off-pump coronary artery bypass grafting, 21 CO was described to be reliably monitored by pulse contour analysis (Vigileo w ) during stable haemodynamic conditions. However, the Vigileo w system showed a tendency to overestimate rapid decreases and increases in CO when compared with the PiCCO w plus system. When compared with ICO bolus measurement, mean bias (2 SDs) (limits of agreement) was 20. Besides a defined study protocol and the same number of measurements per patient, the strength of our study is the stability of CO measurements. In our study, the stability of measurements was in the range of that reported by other studies, i.e. CVs on average were clearly below 10% for both techniques at each of the three time points. However, our study has several limitations. First, we did not use a further technique for comparison, which may independently allow assessment of CO under the study conditions. However, we used transpulmonary thermodilution and not PiCCO w -derived pulse contour, which itself may be influenced by the intervention of changing MAP. Furthermore, we used the Vigileo w system in a manner different from the manufacturer's recommendation. In detail, we used a central (i.e. femoral artery) and not a peripheral (A. radialis) pressure curve and this may have considerably influenced our findings. However, since there was no clinical need for an additional arterial catheter, we could not justify the placement of a second (i.e. peripheral) arterial cannula and we, therefore, used the curve already obtained from the femoral artery. Notably, a new software version for calculating CO is now available and, by applying this version, the results may be different from those in our study. In comparison with previous studies, 10 12 we enrolled a higher number of patients. We analysed a relatively high number of CO measurements with an equal number of measurements per patient under varying haemodynamic conditions while using a backward control. Nevertheless, the number of patients we enrolled (n¼24) is still very limited. Finally, our results are limited insofar as we studied septic patients with reduced peripheral resistance, and these findings are probably not generally applicable to all patients.
In conclusion, pulse contour analysis-derived CO measurements (Vigileo w system) were not correlated with transpulmonary thermodilution and this new system is not as reliable as transpulmonary thermodilution in patients with septic shock.
